Last reviewed · How we verify

NCT05719480

A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer

Status unknown Last updated 9 February 2023
What this trial tests

trial testing Proteomics technology and liquid biopsy in Liver Cancer in 2,000 participants. Status unknown.

Timeline
20 November 2022
Primary endpoint
20 November 2025
20 December 2025

Quick facts

Lead sponsorNanfang Hospital, Southern Medical University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,000
Start date20 November 2022
Primary completion20 November 2025
Estimated completion20 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 70, any sex, with Liver Cancer or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The incidence of liver cancer in China shows a clear clinical path of hepatitis/fatty liver liver cirrhosis liver cancer. The dynamic changes of the internal environment on this pathway are important clues for early detection, diagnosis and even cure of liver cancer. The investigators carried out this study to investigate the changes of plasma and urine metabolites in different liver diseases during the occurrence and development of liver cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Proteomics technology and liquid biopsy

Trials testing the same drug.

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05719480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing